Pharmacokinetics of single intravenous and oral doses of dolasetron mesylate in healthy elderly volunteers

Journal of Clinical Pharmacology

Volumn 36, Issue 10, 1996, Pages 903-910

  Dempsey, Ellen ^a,b   Bourque, Stéphane ^a   Spénard, Jean ^a   Landriault, Hélène ^a  

^a Hoechst Marion Roussel Canada R   (Canada)

^b Hoechst Marion Roussel Canada R   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOLASETRON MESILATE;

AGED; ANTIEMETIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG POTENCY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; QUALITY OF LIFE; VOMITING;

EID: 0029807136     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04757.x     Document Type: Article

References (37)

1. Grunberg SM, Hesketh PJ: Control of chemotherapy-induced emesis. N Engl J Med 1993;329:1790-1796.
2. Clavel M, Soukop M, Greenstreet YLA: Improved control of emesis and quality of life with ondansetron in breast cancer. Oncology 1993;50:180-185.
3. Cooper S, Georgiou V. The impact of cytotoxic chemotherapy: perspectives from patients, specialists and nurses. Eur J Cancer 1992;28A (Suppl 1):S36-S38.
4. Crome P, Flanagan RJ: Pharmacokinetic studies in the elderly: are they necessary? Clin Pharmacokinet 1994;26:243-247.
5. Sloan RW: Principles of drug therapy in geriatric patients. Am Fam Phys 1992;45:2709-2718.
6. Gralla RJ: Current issues in the management of nausea and vomiting. Ann Oncol 1993;4 (Suppl 3):S3-S7.
7. 3 antagonists. Support Care Cancer 1994;2:286-292.
8. 3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. Eur J Pharmacol 1992;219:9-13.
9. 3 receptor antagonist (abstract). Br J Pharmacol 1992;107(Suppl):449P.
10. Galvan M, Gittos MW, Fatmi M: Dolasetron. Drugs Future 1993;18:506-509.
11. 3 receptors. Drug Dev Res 1993;28:87-93.
12. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol 1994;17:97-102.
13. Hesketh PJ, Gandara DR, Hesketh AM, Facada A, Perez EA, Webber LM, et al: Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer 1996;4:141-146.
14. 3 receptors antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann Oncol 1993;4:481-484.
15. Kris MG, Grunberg SM, Gralla RH, Baltzer L, Zaretsky SA, Lifsey D, et al: Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 1994;12:1045-1049.
16. Merrouche Y, Catimel G, Rebattu P, Dumortier A, Guastalla JP, O'Grady P, Clavel M: A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy. Ann Oncol 1994;5: 549-551.
17. Rubenstein E, Kalman L, Hainsworth J, Plezia P, Modiano M, Eisenberg P, et al: Dose-response trial across 4 oral doses of dolasetron for emesis prevention after moderately emetogenic chemotherapy (abstract). Proc Am Soc Clin Oncol 1995;14:527.
18. Harman GS, Omura GA, Ryan K, Hainsworth JD, Cramer MB, Hahne WF: A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol 1996;38:323.
19. Kasimis BS, Tapazoglou E, Schulman P, Tapazoglou E, Schulman P, Howard L, et al: A double-blind, randomized study of two different dose regimens of intravenous dolasetron in patients receiving high-dose cisplatin chemotherapy. Cancer Invest (in press).
20. Yeilding A, Bertoli L, Eisenberg P, Plezia P, Modiano MR, Alberts DS, et al: Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. Am J Clin Oncol (in press).
21. Fauser A, Bleiberg H, Chevallier B, Favre R, Fabbro M, Claverie N, Hahne W: A double-blind randomized comparative trial of IV dolasetron vs IV metoclopramide in prevention of emesis in moderately-emetogenic chemotherapy (abstract). Proc Am Soc Clin Oncol 1995;14:530.
22. Boxenbaum H, Gillespie T, Heck K, Hahne W: Human dolasetron pharmacokinetics. I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 1992;13:693-701.
23. 3 receptor antagonist (abstract). ISSX Proc 1994;6:230.
24. Huebert ND, Zeidler L, Schwartz JJ, Hinze C, Haegele KD: The pharmacokinetics of dolasetron mesilate and its active metabolite, MDL 74,156, in man (abstract no. P12.2.26). Can J Physiol Pharmacol 1994;72(Suppl 1):302.
25. 3 receptor antagonist. Drug Dev Res 1995;34:289-296.
26. Boxenbaum H, Gillespie T, Heck K, Hahne W: Human dolasetron pharmacokinetics. II. Absorption and disposition following single-dose oral administration to normal male subjects. Biopharm Drug Dispos 1993;14:131-141.
27. Choo YS, Dimmitt DC, McElvain JS, Castles MA, Arumugham T, Vandiver VJ, et al: Pharmacokinetics and dose-proportionality of dolasetron mesylate following intravenous administration to healthy volunteers (abstract). Pharm Res 1995;12(Suppl 9):S388.
28. Gillespie TA, Eckstein JA, Nardella P, Coutant JE: Determination of dolasetron and its reduced metabolite in human plasma by GC-MS and LC. J Pharm Biomed 1993;11:955-962.
29. Gibaldi M, Perrier D: Pharmacokinetics. Second edition. New York: Marcel Dekker, 1982.
30. Lippert CL, Dimmitt DC, Eller MG, Weir SJ, Cramer M, Hahne WF: Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapy (abstract). Pharm Res 1995;12 (Suppl 9):S360.
31. Colthup PV, Felgate CC, Palmer JL, Scully NL: Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly. J Pharm Sci 1991;80:868-871.
32. Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL, Powell JR: Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. Clin Pharmacol Ther 1992;51:51-55.
33. Figg WD, Dukes GE, Pritchard JF, et al: Ondansetron pharmacokinetics in chronic liver disease (abstract). Clin Pharmacol Ther 1992;51:171.
34. Addelman M, Erlichman C, Fine S, Warr D, Murray C: Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol 1990;8:337-341.
35. Andrews PLR: The pharmacologic profile of granisetron (Kytril). Semin Oncol 1994;21(Suppl 5):3-9.
36. 3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 1989;24:45-49.
37. Plosker GL, Goa KL: Granisetron: a review of its pharmacokinetic properties and therapeutic use as an antiemetic. Drugs 1991;42:805-824.